AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 18304693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide plus protocol-specified standard therapy
Number of subjects: 101
Study 18304693 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus standard therapy
Number of subjects: 101
Study 18304693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 101
Study 18304693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 18304693 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide and Placebo
Number of subjects: 101
Study 16565626 — intervention group
Group type: EXPERIMENTAL
Intervention: Chan‐Chuang qi‐gong therapy for 21 days
Number of subjects: 67
Study 16565626 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 67
Study 15194373 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction with systemic-enteric drainage (S-E)
Number of subjects: 297
Study 15194373 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction with portal-enteric drainage (P-E)
Number of subjects: 297
Study 15194373 — intervention group
Group type: EXPERIMENTAL
Intervention: Daclizumab induction with systemic-bladder drainage (S-B)
Number of subjects: 297
Study 15194373 — intervention group
Group type: COMPARATOR
Intervention: No-antibody induction
Number of subjects: 297
Study 10856733 — intervention group
Group type: EXPERIMENTAL
Intervention: L-carnitine (2 g/day) added to therapy in group I (n=31)
Number of subjects: 51
Study 10856733 — intervention group
Group type: COMPARATOR
Intervention: Control group (group II, n=20) without L-carnitine
Number of subjects: 51
Study 9062490 — intervention group
Group type: EXPERIMENTAL
Intervention: Acipimox (oral administration during the last 8 hours)
Number of subjects: 9
Study 8342836 — intervention group
Group type: EXPERIMENTAL
Intervention: Esophageal Detector Device (EDD)
Number of subjects: 500
Study 8342836 — intervention group
Group type: COMPARATOR
Intervention: Capnography
Number of subjects: 500
Study 8342836 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall results from EDD
Number of subjects: 500
Study 3518499 — intervention group
Group type: EXPERIMENTAL
Intervention: Women told they would be tested for marijuana, alcohol, and other drugs
Number of subjects: 2
Study 3518499 — intervention group
Group type: COMPARATOR
Intervention: Women not told they would be tested
Number of subjects: 2
Study 3518499 — intervention group
Group type: EXPERIMENTAL
Intervention: Urine assays
Number of subjects: 2
Study 3518499 — intervention group
Group type: EXPERIMENTAL
Intervention: Tested women
Number of subjects: 2
Study 29657206 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose intradermal (ID) route: 10 μg of vaccine weekly for 8 weeks (total 40 μg)
Number of subjects: 56
Study 29657206 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose intradermal (ID) route: 40 μg of vaccine at 1-month intervals (total 80 μg)
Number of subjects: 56
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding intoxicated behaviors
Number of subjects: 221
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding safe drinking strategies
Number of subjects: 221
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding drinking-related consequences
Number of subjects: 221
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: Injunctive norms feedback regarding drinking behaviors of potential partners
Number of subjects: 221
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: General injunctive norms
Number of subjects: 221
Study 26978277 — intervention group
Group type: EXPERIMENTAL
Intervention: Pro-moderation statements
Number of subjects: 221
Study 24279907 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasya/Prevalin
Number of subjects: 20
Study 24279907 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline spray)
Number of subjects: 20
Study 22821660 — intervention group
Group type: EXPERIMENTAL
Intervention: Fuzheng Huayu Tablet (FZHYT)
Number of subjects: 180
Study 22821660 — intervention group
Group type: COMPARATOR
Intervention: Conventional therapy combined with placebo (Control)
Number of subjects: 180
Study 20547620 — intervention group
Group type: EXPERIMENTAL
Intervention: Tubular discectomy
Number of subjects: 0
Study 20547620 — intervention group
Group type: COMPARATOR
Intervention: Conventional microdiscectomy
Number of subjects: 0
Study 18656052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 1A)
Number of subjects: 60
Study 18656052 — intervention group
Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 1B)
Number of subjects: 60
Study 18656052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 2A)
Number of subjects: 60
Study 18656052 — intervention group
Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 2B)
Number of subjects: 60
Study 18656052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 3A)
Number of subjects: 60
Study 18656052 — intervention group
Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 3B)
Number of subjects: 60
Study 18656052 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% CHG soap (group 1A, 2A, 3A)
Number of subjects: 60
Study 18656052 — intervention group
Group type: COMPARATOR
Intervention: 2% CHG-impregnated polyester cloth (group 1B, 2B, 3B)
Number of subjects: 60
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Cast post‐and‐core restorations
Number of subjects: 249
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct post and composite core restorations
Number of subjects: 249
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Post‐free all‐composite cores
Number of subjects: 249
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining dentin height (substantial)
Number of subjects: 249
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining dentin height (minimal)
Number of subjects: 249
Study 15754890 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival rate of all restorations
Number of subjects: 249
Study 12357165 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine infusion
Number of subjects: 30
Study 12357165 — intervention group
Group type: COMPARATOR
Intervention: 0.9% saline infusion
Number of subjects: 30
Study 11408334 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon beta-1b (IFNbeta-1b)
Number of subjects: 95
Study 11408334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study 9236561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride, 0.3 mg/kg
Number of subjects: 45
Study 9236561 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride, 0.7 mg/kg
Number of subjects: 45
Study 9236561 — intervention group
Group type: COMPARATOR
Intervention: Saline solution (Control)
Number of subjects: 45
Study 9236561 — intervention group
Group type: EXPERIMENTAL
Intervention: Nefopam hydrochloride (for control group patients with persistent shivering)
Number of subjects: 45
Study 9236561 — intervention group
Group type: EXPERIMENTAL
Intervention: Meperidine hydrochloride (for control group patients with persistent shivering)
Number of subjects: 45
Study 8435601 — intervention group
Group type: EXPERIMENTAL
Intervention: Family Smoking Education project (FSE)
Number of subjects: 4538
Study 8435601 — intervention group
Group type: EXPERIMENTAL
Intervention: Smoking and Me project (SAM)
Number of subjects: 4538
Study 8435601 — intervention group
Group type: EXPERIMENTAL
Intervention: Both projects in sequence (FSE/SAM)
Number of subjects: 4538
Study 8435601 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 4538
Study 8435601 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups (FSE, SAM, FSE/SAM, Control)
Number of subjects: 4538
Study 3308584 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous insulin
Number of subjects: 0
Study 3308584 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazamide
Number of subjects: 0
Study 3308584 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic subjects
Number of subjects: 0
Study 29936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program
Number of subjects: 96
Study 29936408 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcendental Meditation (TM) program (EEG subgroup)
Number of subjects: 96
Study 29936408 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control group
Number of subjects: 96
Study 26546612 — intervention group
Group type: EXPERIMENTAL
Intervention: Sitagliptin (n=94)
Number of subjects: 141
Study 26546612 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=47)
Number of subjects: 141
Study 25524655 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower intensity exercise program
Number of subjects: 160
Study 25524655 — intervention group
Group type: COMPARATOR
Intervention: Higher intensity exercise program
Number of subjects: 160
Study 22948735 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnified visual feedback (1° and 4°) during position-holding contractions
Number of subjects: 22
Study 22948735 — intervention group
Group type: COMPARATOR
Intervention: No visual feedback (removed from 15 to 25 seconds during trials)
Number of subjects: 22
Study 22948735 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback at 0.1°
Number of subjects: 22
Study 22948735 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback at 1°
Number of subjects: 22
Study 22948735 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual feedback at 4°
Number of subjects: 22
Study 20923005 — intervention group
Group type: EXPERIMENTAL
Intervention: 1,8‐cineol
Number of subjects: 0
Study 20923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Jasmine absolute ether
Number of subjects: 0
Study 20923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Peppermint essential oil
Number of subjects: 0
Study 20923005 — intervention group
Group type: EXPERIMENTAL
Intervention: Linalyl acetate
Number of subjects: 0
Study 20923005 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 18294333 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg single dose in CYP2C19*17/*17 subjects
Number of subjects: 17
Study 18294333 — intervention group
Group type: COMPARATOR
Intervention: Omeprazole 40 mg single dose in CYP2C19*1/*1 subjects
Number of subjects: 17
Study 15772362 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive therapy (IT)
Number of subjects: 142
Study 15772362 — intervention group
Group type: COMPARATOR
Intervention: Usual care (UC)
Number of subjects: 142
Study 12517462 — intervention group
Group type: EXPERIMENTAL
Intervention: Radiofrequency lesioning of dorsal root ganglia
Number of subjects: 83
Study 12517462 — intervention group
Group type: COMPARATOR
Intervention: Control treatment (local anaesthetics)
Number of subjects: 83
Study 11138908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized academic achievement tests in rural population
Number of subjects: 363
Study 11138908 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized academic achievement tests in urban population
Number of subjects: 363
Study 11138908 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological evaluation of children with arithmetic deficits
Number of subjects: 363
Study 8706775 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily for 2 weeks
Number of subjects: 12
Study 8706775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg daily for 2 weeks
Number of subjects: 12
Study 8706775 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg for 1 week
Number of subjects: 12
Study 8706775 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg for 1 week
Number of subjects: 12
Study 1580340 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychoeducational support group
Number of subjects: 55
Study 1580340 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 55
Study 31936428 — intervention group
Group type: EXPERIMENTAL
Intervention: Low GI diet (n = 18)
Number of subjects: 40
Study 31936428 — intervention group
Group type: COMPARATOR
Intervention: Control diet (n = 18)
Number of subjects: 40
Study 31689118 — intervention group
Group type: COMPARATOR
Intervention: Coffee with 0g MCT
Number of subjects: 10
Study 31689118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with 28g MCT
Number of subjects: 10
Study 31689118 — intervention group
Group type: EXPERIMENTAL
Intervention: Coffee with 42g MCT
Number of subjects: 10
Study 28190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Tiered consent and controlled data sharing
Number of subjects: 13000
Study 28190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad consent and controlled data sharing
Number of subjects: 13000
Study 28190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Broad consent and open data sharing
Number of subjects: 13000
Study 28190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population-weighted respondents
Number of subjects: 13000
Study 28190457 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall participants
Number of subjects: 13000
Study 25923045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil at three target‐site concentrations: 1, 2, and 3 ng/ml
Number of subjects: 14
Study 25923045 — intervention group
Group type: COMPARATOR
Intervention: Naloxone (6 μg/kg bolus followed by 0.1 μg/kg/min infusion)
Number of subjects: 14
Study 25923045 — intervention group
Group type: COMPARATOR
Intervention: Saline (control group)
Number of subjects: 14
Study 25923045 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoclopramide (0.2 mg/kg)
Number of subjects: 14
Study 25923045 — intervention group
Group type: EXPERIMENTAL
Intervention: Remifentanil before and after metoclopramide administration
Number of subjects: 14
Study 25798508 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-week group psychotherapy intervention (New Beginnings program)
Number of subjects: 0
Study 22795863 — intervention group
Group type: EXPERIMENTAL
Intervention: Seal-In liner
Number of subjects: 9
Study 22795863 — intervention group
Group type: COMPARATOR
Intervention: Dermo liner
Number of subjects: 9
Study 22795863 — intervention group
Group type: EXPERIMENTAL
Intervention: Both liners
Number of subjects: 9
Study 20647058 — intervention group
Group type: EXPERIMENTAL
Intervention: Improved medication labels
Number of subjects: 0
Study 20647058 — intervention group
Group type: COMPARATOR
Intervention: Standard labels
Number of subjects: 0
Study 17470735 — intervention group
Group type: EXPERIMENTAL
Intervention: 2% testosterone in Vanicream (10 mg daily)
Number of subjects: 150
Study 17470735 — intervention group
Group type: COMPARATOR
Intervention: Placebo Vanicream
Number of subjects: 150
Study 17470735 — intervention group
Group type: EXPERIMENTAL
Intervention: Both testosterone and placebo
Number of subjects: 150
Study 15006032 — intervention group
Group type: COMPARATOR
Intervention: Healthy control subjects
Number of subjects: 0
Study 15006032 — intervention group
Group type: EXPERIMENTAL
Intervention: Amnesic patients with extensive medial temporal lobe damage
Number of subjects: 0
Study 15006032 — intervention group
Group type: EXPERIMENTAL
Intervention: Mild hypoxic patients with selective hippocampal damage
Number of subjects: 0
Study 15006032 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient with thalamic lesions
Number of subjects: 0
Study 12575232 — intervention group
Group type: EXPERIMENTAL
Intervention: nao-yi-an treatment
Number of subjects: 0
Study 12575232 — intervention group
Group type: COMPARATOR
Intervention: medicine control group
Number of subjects: 0
Study 12575232 — intervention group
Group type: COMPARATOR
Intervention: healthy control group
Number of subjects: 0
Study 10319667 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadruple therapy (amoxycillin 500 mg t.i.d., metronidazole 500 mg t.i.d., furoxone 100 mg t.i.d. for 5 days during the 3rd week) + ranitidine 300 mg daily for 8 weeks
Number of subjects: 51
Study 10319667 — intervention group
Group type: COMPARATOR
Intervention: Ranitidine 150 mg daily for 12 months
Number of subjects: 51
Study 7635369 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymphocyte immunotherapy (LI) + Progesterone (P)
Number of subjects: 66
Study 7635369 — intervention group
Group type: COMPARATOR
Intervention: Progesterone alone
Number of subjects: 66
Study 2793265 — intervention group
Group type: EXPERIMENTAL
Intervention: Labetalol (200 mg)
Number of subjects: 29
Study 2793265 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (100 mg) plus Nifedipine (10 mg)
Number of subjects: 29
Study 2793265 — intervention group
Group type: COMPARATOR
Intervention: Both regimens
Number of subjects: 29
Study 694487 — intervention group
Group type: EXPERIMENTAL
Intervention: Antibiotics plus granulocyte transfusions (1.7‐14.7 X 10(10) granulocytes by 1‐5 daily transfusions, mean 6.6 X 10(10))
Number of subjects: 25
Study 694487 — intervention group
Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 25
Study 30829619 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF (administered every 4 weeks for 80 weeks)
Number of subjects: 41
Study 30829619 — intervention group
Group type: COMPARATOR
Intervention: GDNF (after 40 weeks of placebo)
Number of subjects: 41
Study 30829619 — intervention group
Group type: EXPERIMENTAL
Intervention: GDNF/GDNF (Week 80)
Number of subjects: 41
Study 30829619 — intervention group
Group type: COMPARATOR
Intervention: Placebo/GDNF (Week 40)
Number of subjects: 41
Study 28301671 — intervention group
Group type: EXPERIMENTAL
Intervention: BMSCs plus penicillamine
Number of subjects: 60
Study 28301671 — intervention group
Group type: COMPARATOR
Intervention: Penicillamine
Number of subjects: 60
Study 26130141 — intervention group
Group type: EXPERIMENTAL
Intervention: 48 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Number of subjects: 187
Study 26130141 — intervention group
Group type: COMPARATOR
Intervention: 24 weeks of Peginterferon (Peg‐IFN) alfa‐2a 180 μg/week plus weight-based ribavirin (RBV) 1,000‐1,200 mg/day
Number of subjects: 187
Study 24359229 — intervention group
Group type: EXPERIMENTAL
Intervention: ZRADSQ (Zheng-related atopic dermatitis symptom questionnaire)
Number of subjects: 188
Study 24359229 — intervention group
Group type: EXPERIMENTAL
Intervention: ZRADSQ
Number of subjects: 188
Study 22084960 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardiac TRUST intervention group
Number of subjects: 38
Study 22084960 — intervention group
Group type: COMPARATOR
Intervention: Usual care group
Number of subjects: 38
Study 19689237 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive training (reasoning and speed of processing)
Number of subjects: 3000
Study 19689237 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory training
Number of subjects: 3000
Study 19689237 — intervention group
Group type: EXPERIMENTAL
Intervention: Reasoning and speed of processing training
Number of subjects: 3000
Study 16676701 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeine ingestion (6 mg/kg body mass)
Number of subjects: 19
Study 16676701 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 19
Study 15567646 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients who agreed to participate in the survey (consenters)
Number of subjects: 52
Study 15567646 — intervention group
Group type: COMPARATOR
Intervention: Patients who declined to participate in the survey (nonconsenters)
Number of subjects: 52
Study 15567646 — intervention group
Group type: EXPERIMENTAL
Intervention: Older age (>60 yrs)
Number of subjects: 52
Study 15567646 — intervention group
Group type: EXPERIMENTAL
Intervention: Reassuring attitude conveyed by study personnel
Number of subjects: 52
Study 15567646 — intervention group
Group type: EXPERIMENTAL
Intervention: Trust in study personnel
Number of subjects: 52
Study 15567646 — intervention group
Group type: COMPARATOR
Intervention: Perception of being a 'guinea pig'
Number of subjects: 52
Study 10945318 — intervention group
Group type: EXPERIMENTAL
Intervention: RIG200 (6 nmol/min infusion)
Number of subjects: 14
Study 10945318 — intervention group
Group type: COMPARATOR
Intervention: Sodium nitroprusside (0.06 nmol/min infusion)
Number of subjects: 14
Study 9076208 — intervention group
Group type: EXPERIMENTAL
Intervention: Coagulase-negative staphylococci (CoNS) cultured from the anterior chamber and vitreous
Number of subjects: 225
Study 9076208 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-S epidermidis CoNS
Number of subjects: 225
Study 8093340 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure (IVE)
Number of subjects: 48
Study 8093340 — intervention group
Group type: COMPARATOR
Intervention: Vicarious exposure (VE)
Number of subjects: 48
Study 8093340 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo exposure plus vicarious exposure (IVVE)
Number of subjects: 48
Study 8093340 — intervention group
Group type: COMPARATOR
Intervention: Assessment only control
Number of subjects: 48
Study 2943050 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ipratropium bromide (200 micrograms three times daily for four weeks)
Number of subjects: 15
Study 2943050 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 15
Study 2943050 — intervention group
Group type: EXPERIMENTAL
Intervention: High dose ipratropium bromide
Number of subjects: 15
Study 29387936 — intervention group
Group type: EXPERIMENTAL
Intervention: Group cognitive behavioral therapy (CBT) for insomnia
Number of subjects: 51
Study 29387936 — intervention group
Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 51
Study 26316089 — intervention group
Group type: EXPERIMENTAL
Intervention: Total Knee Replacement Surgery (TKR)
Number of subjects: 390
Study 25664657 — intervention group
Group type: EXPERIMENTAL
Intervention: Worsening trajectories of inattention symptoms and delinquency
Number of subjects: 579
Study 25664657 — intervention group
Group type: COMPARATOR
Intervention: Stable or improving trajectories of inattention symptoms and delinquency
Number of subjects: 579
Study 23076383 — intervention group
Group type: EXPERIMENTAL
Intervention: Coadministration of 10-valent pneumococcal conjugate vaccine (PHiD-CV) and tetravalent meningococcal conjugate vaccine (MenACWY-TT)
Number of subjects: 363
Study 23076383 — intervention group
Group type: COMPARATOR
Intervention: MenACWY-TT alone
Number of subjects: 363
Study 23076383 — intervention group
Group type: COMPARATOR
Intervention: PHiD-CV alone
Number of subjects: 363